A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer

Cancer patients often display dysfunctional antitumor T-cell responses. Because noteworthy benefits of immune checkpoint pathway blockade, such as programmed cell death protein 1 (PD-1) inhibitors, have been achieved in multiple advanced cancers, the next critical question is which mono-blockade or...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in oncology Jg. 9; S. 1066
Hauptverfasser: Li, Xi, Wang, Rouzheng, Fan, Peiwen, Yao, Xuan, Qin, Ling, Peng, Yanchun, Ma, Miaomiao, Asley, Neil, Chang, Xuimei, Feng, Yaning, Hu, Yunhui, Zhang, Yonghong, Li, Chris, Fanning, Gregory, Jones, Stephanie, Verrill, Clare, Maldonado-Perez, David, Sopp, Paul, Waugh, Craig, Taylor, Stephen, Mcgowan, Simon, Cerundolo, Vincenzo, Conlon, Christopher, McMichael, Andrew, Lu, Shichun, Wang, Xiyan, Li, Ning, Dong, Tao
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 25.10.2019
Schlagworte:
combinatorial checkpoint blockade
inhibitory receptor
Oncology
T cells
tumor microenvironment
tumor-infiltrating lymphocytes
combinatorial checkpoint blockade
tumor-infiltrating lymphocytes
inhibitory receptor
tumor microenvironment
T cells
ISSN:2234-943X, 2234-943X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cancer patients often display dysfunctional antitumor T-cell responses. Because noteworthy benefits of immune checkpoint pathway blockade, such as programmed cell death protein 1 (PD-1) inhibitors, have been achieved in multiple advanced cancers, the next critical question is which mono-blockade or combinatorial blockade regimens may reinvigorate antitumor T-cell immunity in those cancer patients while limiting immune-related adverse effects. This study recruited, in total, 172 primary cancer patients (131 were blood-tumor-matched patients) who were treatment-naïve prior to the surgeries or biopsies covering the eight most prevalent types of cancer. With access to fresh surgical samples, this study simultaneously investigated the expression level of eight known immune checkpoint receptors [PD-1, cytotoxic T-lymphocyte antigen-4 [CTLA-4], T-cell immunoglobulin and mucin-domain containing-3 [Tim-3], 2B4, killer cell lectin like receptor G1 [KLRG-1], TIGIT, B- and T-lymphocyte attenuator [BTLA], and CD160] on tumor-infiltrating T cells (TILs) and paired circulating T cells in blood from a 131-patient cohort. We found increased an expression of PD-1 and Tim-3 but a decreased expression of BTLA on TILs when compared with peripheral blood from multiple types of cancer. Moreover, our co-expression analysis of key immune checkpoint receptors delineates "shared" subsets as PD-1+Tim-3+TIGIT+2B4+KLRG-1-CTLA-4- and PD-1+TIGIT+2B4+Tim-3-KLRG-1-CTLA-4- from bulk CD8 TILs. Furthermore, we found that a higher frequency of advanced differentiation stage T cells (CD27-CCR7-CD45RA-) among the "shared" subset (PD-1+Tim-3+TIGIT+2B4+KLRG-1-CTLA-4-) in bulk CD8 TILs was associated with poorly differentiated cancer type in cervical cancer patients. To our knowledge, our study is the first comprehensive analysis of key immune checkpoint receptors on T cells in treatment-naïve, primary cancer patients from the eight most prevalent types of cancer. These findings might provide useful information for future design of mono-blockade/combinatorial blockades and/or genetically modified T-cell immunotherapy.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
Reviewed by: Daniel E. Speiser, Université de Lausanne, Switzerland; Cecile Gouttefangeas, University of Tübingen, Germany
Edited by: Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche des Cordeliers, France
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2019.01066